Literature DB >> 26768032

Ductal carcinoma in situ - update on risk assessment and management.

Jia-Min B Pang1,2, Kylie L Gorringe2,3,4, Stephen B Fox1,2,3.   

Abstract

Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  breast neoplasms; clinical markers; clinical pathology; patient care management

Mesh：

Year:  2016        PMID： 26768032     DOI： 10.1111/his.12796

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


  14 in total

Review 1.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

2.  Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Authors:  Serdar Altinay; Laurent Arnould; Noella Bletard; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchió; Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer M Shaaban; Renata Sinke; Claudia Maria Stanciu-Pop; Claudia Stobbe; Carolien H M van Deurzen; Koen Van de Vijver; Anne-Sophie Van Rompuy; Stephanie Verschuere; Anne Vincent-Salomon; Hannah Wen; Hélène Dano; Caroline Bouzin; Christine Galant; Mieke R Van Bockstal
Journal:  Mod Pathol       Date:  2019-09-18       Impact factor: 7.842

3.  Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms.

Authors:  Gage Brummer; Diana S Acevedo; Qingting Hu; Mike Portsche; Wei Bin Fang; Min Yao; Brandon Zinda; Megan Myers; Nehemiah Alvarez; Patrick Fields; Yan Hong; Fariba Behbod; Nikki Cheng
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

Review 4.  Importance of cost-effectiveness and value in cancer care and healthcare policy.

Authors:  Ravinder Kang; Philip P Goodney; Sandra L Wong
Journal:  J Surg Oncol       Date:  2016-06-22       Impact factor: 3.454

5.  Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?

Authors:  Tawakalitu O Oseni; Barbara L Smith; Constance D Lehman; Charmi A Vijapura; Niveditha Pinnamaneni; Manisha Bahl
Journal:  Ann Surg Oncol       Date:  2020-05-16       Impact factor: 5.344

6.  Essential role of STAT5a in DCIS formation and invasion following estrogen treatment.

Authors:  Sundee Dees; Laura Pontiggia; Jean-Francois Jasmin; Federica Sotgia; Michael P Lisanti; Isabelle Mercier
Journal:  Aging (Albany NY)       Date:  2020-08-05       Impact factor: 5.682

7.  Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.

Authors:  Valeria Bertagnolo; Silvia Grassilli; Stefano Volinia; Yasamin Al-Qassab; Federica Brugnoli; Federica Vezzali; Elisabetta Lambertini; Maria Palomba; Quirino Piubello; Enrico Orvieto; Cristina Natali; Roberta Piva; Carlo Maria Croce; Silvano Capitani
Journal:  Mol Carcinog       Date:  2019-01-16       Impact factor: 4.784

8.  Implementation of shared decision-making in oncology: development and pilot study of a nurse-led decision-coaching programme for women with ductal carcinoma in situ.

Authors:  Birte Berger-Höger; Katrin Liethmann; Ingrid Mühlhauser; Anke Steckelberg
Journal:  BMC Med Inform Decis Mak       Date:  2017-12-06       Impact factor: 2.796

9.  Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.

Authors:  Marie Beguinot; Marie-Melanie Dauplat; Fabrice Kwiatkowski; Guillaume Lebouedec; Lucie Tixier; Christophe Pomel; Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  BMC Cancer       Date:  2018-02-03       Impact factor: 4.430

Review 10.  Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.

Authors:  Tanjina Kader; Prue Hill; Emad A Rakha; Ian G Campbell; Kylie L Gorringe
Journal:  Breast Cancer Res       Date:  2018-05-02       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.